- Conditions
- Alzheimer Disease, Dementia
- Interventions
- PorchLight Project
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 1,989
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer's Disease (AD)
- Interventions
- Oxaloacetate (OAA) 1g, Oxaloacetate (OAA) 2g
- Drug
- Lead sponsor
- Russell Swerdlow
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Alzheimer Disease
- Interventions
- ACU193, Placebo
- Drug
- Lead sponsor
- Acumen Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Anaheim, California • Newport Beach, California + 14 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Interventions
- [18F]APN-1607
- Drug
- Lead sponsor
- APRINOIA Therapeutics, LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Mount Arlington, New Jersey • New York, New York
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Insulin aspart, Placebo
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Alzheimer's Disease
- Interventions
- SB-742457 15mg, SB-742457 35mg, Placebo, donepezil 5-10mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Litchfield Park, Arizona • Fresno, California • Rancho Mirage, California + 11 more
- Conditions
- Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Interventions
- high CBD/low THC sublingual solution
- Drug
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Alzheimer Disease, Aging, MCI
- Interventions
- TMS
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alzheimer Disease
- Interventions
- AL002, Placebo
- Drug
- Lead sponsor
- Alector Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • Costa Mesa, California + 25 more
- Conditions
- Healthy
- Interventions
- GSI-953
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Dementia, Alzheimer's Disease
- Interventions
- [18F]NAV4694
- Drug
- Lead sponsor
- Navidea Biopharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 15
- States / cities
- Sun City, Arizona • La Jolla, California • Fort Myers, Florida + 12 more
- Conditions
- Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
- Interventions
- C-11 ER-176, Blood Test
- Drug · Diagnostic Test
- Lead sponsor
- Val Lowe
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Alzheimer Disease (AD)
- Interventions
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer's Disease
- Interventions
- florbetapir F 18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- CX516, Placebo
- Drug
- Lead sponsor
- RespireRx
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 8
- States / cities
- Peoria, Arizona • Irvine, California • Los Angeles, California + 5 more
- Conditions
- Alzheimer's Disease
- Interventions
- florbetapir F 18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease, Neurodegenerative Diseases
- Interventions
- Cytology and Immunohistochemistry
- Diagnostic Test
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 19 Years to 89 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular
- Interventions
- Citalopram [Celexa], Perphenazine [Trilafon]
- Drug
- Lead sponsor
- Bruce Pollock
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2002
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Interventions
- Florbetapir F 18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,768 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2017
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more
- Conditions
- Alzheimer Disease
- Interventions
- BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Colton, California • Long Beach, California • Redlands, California + 12 more
- Conditions
- Cognitive Impairment, Vascular Diseases, Alzheimer Disease, Atherosclerosis
- Interventions
- 11C-PIB
- Drug
- Lead sponsor
- José A. Luchsinger
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cognitively Healthy People, Alzheimer Disease
- Interventions
- GENUS, Tactile GENUS
- Device
- Lead sponsor
- Massachusetts Institute of Technology
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
- Interventions
- PU-AD, PET Scan, Blood Draws
- Drug · Device · Other
- Lead sponsor
- Samus Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type
- Interventions
- Placebo, AVP-786
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 93
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more